Evaluation of Wnt5a and LRP5 Levels in Serum and Saliva Samples and the Relationship Between Clinical Periodontal Parameters

NCT06933784 | Completed

• 2 other identifiers: 36290600/02/20241919B012324587
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Objectives: Wnt5a is a secreted Wnt ligand that plays an important role in cellular homeostasis. Wnt interaction with coreceptor low-density lipoprotein receptor-related protein 5 (LRP5) induces the proliferation of osteoblasts and prolongs their functional life. The aim of this study is evaluating the levels of Wnt5a and LRP5 in serum and saliva samples and relationship between clinical periodontal parameters. Method: Saliva and serum samples were collected from 20 systemically healthy patients with stage III periodontitis and 20 periodontally healthy controls. Wnt5a and LRP5 levels were measured using enzyme-linked immunosorbent assay (ELISA). Clinical periodontal parameters including plaque index (PI), probing pocket depth (PPD), bleeding on probing (BOP), and clinical attachment level (CAL) were recorded.

Conditions

Periodontal Disease; Periodontitis (Stage 3); Periodontitis Stage III

Keywords

Wnt5a; LRP5; periodontitis

Outcome Measures

Primary Outcomes (2)

• Wnt5a

  Wnt5a is synthesized by activated antigen-presenting cells and its expression is induced by mycobacterial cell wall components and endotoxin in human antigen-presenting cells, and Wnt5a signaling is required for the overall inflammatory response of human macrophages during sepsis.The levels of Wnt5a in both serum and saliva samples were determined using commercially available ELISA kits. All assays were conducted according to the manufacturers' instructions.

  1 month

• LRP5

  Low-density lipoprotein (LDL) receptor-related protein 5 (LRP5) is a WNT coreceptor in the LRP superfamily involved in a wide range of biological processes including endocytosis, cellular communication, lipid homeostasis and embryonic development. The levels of LRP5 in both serum and saliva samples were determined using commercially available ELISA kits. All assays were conducted according to the manufacturers' instructions.

  1 month

Study Arms (2)

Stage III periodontitis Grade B

Individuals exhibiting pocket depths of \>3 mm in at least two non-adjacent teeth, radiographic evidence of alveolar bone loss extending to the middle or apical third of the root, and tooth loss of ≤4 due to periodontitis were classified as having Stage III periodontitis. The additional criterion for Grade B classification was defined as a % bone loss/age ratio of 0.25-1.

Periodontally healthy

Individuals with no signs of alveolar bone loss and an overall oral bleeding score \<10% were categorized as periodontally healthy.

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population consisted of patients with stage III periodontitis and periodontally healthy patients admitted to Ankara University Faculty of Dentistry Clinic.

You may qualify if:

• \>18 years old,
• At least 16 permanent teeth except 3rd molars,
• Individuals who do not use orthodontic appliances,
• Individuals who are not pregnant or lactating,
• Individuals without any systemic disease that may affect periodontal health,
• Systemically healthy individuals,
• Individuals who have not used anti-inflammatory and/or anti-microbial drugs in the last 6 months,
• Individuals who have not received periodontal treatment in the last 1 year

You may not qualify if:

• Pregnant/lactating individuals,
• Individuals who have used anti-inflammatory and/or anti-microbial drugs in the last 6 months,
• Individuals who have undergone periodontal treatment in the last 1 year,
• Individuals with psychiatric illness,
• Individuals with any oral infection,
• Individuals with \<16 teeth, excluding molars,
• Individuals with alcohol dependence,
• Individuals with active infectious disease (acute hepatitis, AIDS, tuberculosis), cancer or any systemic condition that may affect periodontal tissues,
• Individuals receiving treatment with drugs known to affect periodontal tissues (phenytoin, cyclosporine A, calcium channel blockers)

Sponsors & Collaborators

• Ankara University: lead
• The Scientific and Technological Research Council of Turkey: collaborator

Study Sites (1)

Ankara University, Faculty of Dentistry

Ankara, Yenimahalle, 06500, Turkey (Türkiye)

Location

Related Publications (3)

• Guney Z, Kurgan S, Onder C, Tayman MA, Gunhan O, Kantarci A, Serdar MA, Gunhan M. Wnt signaling in periodontitis. Clin Oral Investig. 2023 Nov;27(11):6801-6812. doi: 10.1007/s00784-023-05294-7. Epub 2023 Oct 10.

  PMID: 37814163 BACKGROUND

• Zhao Y, Zhang C, Huang Y, Yu Y, Li R, Li M, Liu N, Liu P, Qiao J. Up-regulated expression of WNT5a increases inflammation and oxidative stress via PI3K/AKT/NF-kappaB signaling in the granulosa cells of PCOS patients. J Clin Endocrinol Metab. 2015 Jan;100(1):201-11. doi: 10.1210/jc.2014-2419.

  PMID: 25303486 BACKGROUND

• Williams BO, Insogna KL. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone. J Bone Miner Res. 2009 Feb;24(2):171-8. doi: 10.1359/jbmr.081235.

  PMID: 19072724 BACKGROUND

MeSH Terms

Conditions

Periodontal Diseases; Periodontitis

Condition Hierarchy (Ancestors)

Mouth Diseases; Stomatognathic Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Target Duration: 1 Day
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Sub-Investigator

Study Record Dates

• First Submitted: April 9, 2025
• First Posted: April 18, 2025
• Study Start: April 1, 2024
• Primary Completion: October 1, 2024
• Study Completion: March 1, 2025
• Last Updated: April 18, 2025

Record last verified: 2025-04

Locations

TU (1)